|
Indications And Usage Bupropion Hydrochloride Extended-Release Tablets (Sr) Are Indicated For The Treatment Of Major Depressive Disorder. The Efficacy Of Bupropion In The Treatment Of A Major Depressive Episode Was Established In Two 4-Week Controlled Trials Of Depressed Inpatients And In One 6-Week Controlled Trial Of Depressed Outpatients Whose Diagnoses Corresponded Most Closely To The Major Depression Category Of The Apa Diagnostic And Statistical Manual (Dsm) (See Clinical Pharmacology ). A Major Depressive Episode (Dsm-Iv) Implies The Presence Of 1) Depressed Mood Or 2) Loss Of Interest Or Pleasure; In Addition, At Least 5 Of The Following Symptoms Have Been Present During The Same 2-Week Period And Represent A Change From Previous Functioning: Depressed Mood, Markedly Diminished Interest Or Pleasure In Usual Activities, Significant Change In Weight And/or Appetite, Insomnia Or Hypersomnia, Psychomotor Agitation Or Retardation, Increased Fatigue, Feelings Of Guilt Or Worthlessness, Slowed Thinking Or Impaired Concentration, A Suicide Attempt Or Suicidal Ideation. The Efficacy Of Bupropion Hydrochloride Extended-Release Tablets (Sr) In Maintaining An Antidepressant Response For Up To 44 Weeks Following 8 Weeks Of Acute Treatment Was Demonstrated In A Placebo-Controlled Trial (See Clinical Pharmacology ). Nevertheless, The Physician Who Elects To Use Bupropion Hydrochloride Extended-Release Tablets (Sr) For Extended Periods Should Periodically Reevaluate The Long-Term Usefulness Of The Drug For The Individual Patient.
|